insights_auto
Why is DMN down ၂.၃၁%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
၀.၀၆၈ €
arrow_downward
-၂.၃၁%(-၀.၀၀၁၆) 1D
နို ၁၀, GMT+၁ ၂၂:၀၀:၀၀ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
၀.၀၇ €
High
၀.၀၇ €
Low
၀.၀၇ €
Mkt. cap
၁၄.၇၁ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၂
Open
၀.၀၇ €
High
၀.၀၇ €
Low
၀.၀၇ €
Mkt. cap
၁၄.၇၁ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၂
News stories
From web sources and news partners
Seeking Alpha
·
ပြီးခဲ့သည့် ၄၅ မိနစ်
Anthropic opens Australian retail IPO as demand builds ahead of Nasdaq debut (ANT:Pending)
FOREX.com
·
ပြီးခဲ့သည့် ၄၄ မိနစ်
Nasdaq 100 Outlook: Slingshot rally or false dawn?
Benzinga
·
ပြီးခဲ့သည့် ၁ နာရီ
Dow Falls Over 150 Points Following Inflation Report: Greed Index Remains In ‘Fear’ Zone
Bloomberg.com
·
ပြီးခဲ့သည့် ၄၀ မိနစ်
Asian Stocks, Bonds to Drop as Fed Hike Bets Mount: Markets Wrap
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB